Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Esophageal Cancer

Esophageal Cancer

16 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Esophageal Cancer

140 trials tracked for Esophageal Cancer: 16 in phase 3 or 4 and 12 with published results. The most-cited published study has 1257 citations.

140Trials tracked
16Phase 3 & 4
0Recruiting
12With published results
Phase distribution
Phase 4 3 Phase 3 13 Phase 2 95 Phase 1 6 Other / NA 23
  1. Phase 3 Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer Completed · 1,257 cited
  2. Phase 3 A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma Completed · 326 cited
  3. Phase 3 A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma Completed · 319 cited
  4. Phase 3 Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer Completed · 213 cited
  5. Phase 3 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Completed · 134 cited
  6. Phase 4 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed · 113 cited
Show 44 more trials
  1. Phase 3 Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Completed · 106 cited
  2. Phase 3 A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma Completed · 73 cited
  3. Phase 3 First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590) Completed · 41 cited
  4. Phase 3 Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) Completed · 22 cited
  5. Phase 3 A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma Completed · 12 cited
  6. Phase 3 Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer Completed · 3 cited
  7. Phase 4 Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus. Completed
  8. Phase 4 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed
  9. Phase 3 Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma Completed
  10. Phase 3 A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia Completed
  11. Phase 2 Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer Completed
  12. Phase 2 Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer Completed
  13. Phase 2 Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer Completed
  14. Phase 2 Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery Completed
  15. Phase 2 A Study of Patients Receiving High-Dose Rate Brachytherapy Completed
  16. Phase 2 Bupropion in Helping Adults Stop Smoking Completed
  17. Phase 2 IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer Completed
  18. Phase 2 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) Completed
  19. Phase 2 Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. Completed
  20. Phase 2 Sutent + Taxol for Advanced Esophageal Cancer Completed
  21. Phase 2 Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction Completed
  22. Phase 2 Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma Completed
  23. Phase 2 Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia Completed
  24. Phase 2 S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction Completed
  25. Phase 2 Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma Completed
  26. Phase 2 S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer Completed
  27. Phase 2 A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors Completed
  28. Phase 2 Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin Completed
  29. Phase 2 Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy Completed
  30. Phase 2 Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer Completed
  31. Phase 2 Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer Completed
  32. Phase 2 Neoadjuvant Paclitaxel Poliglumex, Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial (CTI#X64001) Completed
  33. Phase 2 KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer Completed
  34. Phase 2 FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer Completed
  35. Phase 2 Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer Completed
  36. Phase 2 Trimodality Management of T1b Esophageal Cancers Completed
  37. Phase 2 Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer Completed
  38. Phase 2 Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer Completed
  39. Phase 2 Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma Completed
  40. Phase 2 Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer Completed
  41. Phase 2 Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma Completed
  42. Phase 2 Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma Completed
  43. Phase 2 Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer Completed
  44. Phase 2 Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery Completed

Showing the 50 most-cited and recently-updated of 140 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Physical exercise during neoadjuvant chemotherapy does not significantly improve pathologic complete response in solid tumors
Oncology Meta-analysis
Physical exercise during neoadjuvant chemotherapy does not significantly improve pathologic complete response in solid tumors Exercise and chemotherapy results for several types of cancer
This meta-analysis of 504 patients with breast, esophageal, gastric, or rectal cancer found no significant difference in pathologic complete…
New data looks at how exercise affects how well chemotherapy shrinks tumors in patients with breast, esophageal, gastric, and rectal cancers…
Sep 10, 2026
Physical frailty tops risk factors for pneumonia after esophagectomy, meta-analysis finds
Geriatrics & Aging Meta-analysis
Physical frailty tops risk factors for pneumonia after esophagectomy, meta-analysis finds Physical frailty and muscle loss increase pneumonia risk after surgery
This meta-analysis of 60 cohort studies in esophageal cancer patients undergoing esophagectomy identified physical frailty as the highest-ra…
Patients with esophageal cancer face a higher risk of pneumonia after surgery if they show signs of physical frailty or muscle loss.
Sep 6, 2026
Genetic liability for cannabis use is causally linked to increased risk of esophageal and lung cancers
Genetics & Precision Medicine Meta-analysis
Genetic liability for cannabis use is causally linked to increased risk of esophageal and lung cancers Genetic data reveals link between cannabis use and certain cancers
This meta-analysis using two-sample Mendelian Randomization evaluates the causal link between genetic liability to cannabis use and specific…
New research using genetic markers shows that a person's genetic tendency toward cannabis use may impact risks for lung, esophageal, and pan…
medRxiv Aug 22, 2026
Nanotechnology may overcome immune checkpoint blockade resistance in esophageal cancer by reprogramming the tumor microenvironment
Allergy & Immunology Sys. Review
Nanotechnology may overcome immune checkpoint blockade resistance in esophageal cancer by reprogramming the tumor microenvironment Nanotechnology May Help Overcome Treatment Resistance in Esophageal Cancer
This systematic review examines how nanotechnology-enabled immunomodulation can reprogram the tumor microenvironment in esophageal cancer, p…
New research explores how nanotechnology can change the tumor environment to help immune checkpoint treatments work better for esophageal ca…
Frontiers Aug 15, 2026
Pretreatment Creatinine to Cystatin C Ratio Predicts Survival in Gastrointestinal Cancers
Nutrition & Obesity Medicine Meta-analysis
Pretreatment Creatinine to Cystatin C Ratio Predicts Survival in Gastrointestinal Cancers Lower Creatinine to Cystatin C Ratio Linked to Shorter Survival
A meta-analysis of 3,073 patients indicates that a lower creatinine-to-cystatin C ratio correlates with significantly poorer survival outcom…
A new analysis suggests that the creatinine-to-cystatin C ratio may help predict survival outcomes for patients with certain digestive tract…
Frontiers Aug 6, 2026
Perioperative tube-fed enteral nutrition management for esophageal cancer involves nine key clinical aspects
Nutrition & Obesity Medicine Meta-analysis
Perioperative tube-fed enteral nutrition management for esophageal cancer involves nine key clinical aspects Guidelines Help Manage Tube Feeding for Esophageal Cancer Patients
This evidence summary synthesizes 40 pieces of evidence from 20 articles regarding perioperative tube-fed enteral nutrition in patients with…
Newer summaries of clinical evidence help healthcare teams better manage tube-fed nutrition for patients undergoing treatment for esophageal…
Frontiers Aug 6, 2026
Hybrid minimally invasive oesophagectomy associated with lower rates of conduit necrosis, pneumonia, and nerve paralysis
ENT (Otolaryngology) Meta-analysis
Hybrid minimally invasive oesophagectomy associated with lower rates of conduit necrosis, pneumonia, and nerve paralysis Hybrid minimally invasive surgery shows fewer complications for esophageal cancer
This meta-analysis of 8 studies involving 6053 patients with oesophageal cancer found that hybrid minimally invasive oesophagectomy (HMIE) s…
A large review of surgical data suggests that a hybrid minimally invasive approach may reduce specific risks like pneumonia and nerve damage…
Jul 31, 2026
Endoscopic resection followed by esophagectomy shows favorable recurrence-free and disease-specific survival in superficial esophageal cancer
Oncology Meta-analysis
Endoscopic resection followed by esophagectomy shows favorable recurrence-free and disease-specific survival in superficial esophageal cancer Combined endoscopic surgery and esophagectomy may improve cancer outcomes
This systematic review and network meta-analysis of 2,621 patients with high-risk superficial esophageal cancer found that endoscopic resect…
A new analysis suggests that combining endoscopic resection with surgery could help patients with high-risk esophageal cancer live longer wi…
Frontiers Jul 25, 2026
Epigallocatechin-3-gallate shows positive therapeutic effects on various digestive system diseases in animal models
Oncology Meta-analysis
Epigallocatechin-3-gallate shows positive therapeutic effects on various digestive system diseases in animal models Green tea compound shows potential for several digestive diseases
This meta-analysis of 63 preclinical studies involving 738 animals indicates that Epigallocatechin-3-gallate (EGCG) has a positive therapeut…
A review of animal studies suggests a green tea compound could help treat various cancers and digestive conditions.
Frontiers Jun 11, 2026
Conversion surgery after induction therapy improves 5-year survival to 26.5% versus 11.6% in cT4 esophageal cancer patients
ENT (Otolaryngology) Meta-analysis
Conversion surgery after induction therapy improves 5-year survival to 26.5% versus 11.6% in cT4 esophageal cancer patients Conversion surgery after induction therapy improves survival for advanced esophageal cancer patients
This systematic review and meta-analysis evaluates conversion surgery versus definitive therapy for patients with cT4 esophageal cancer. The…
Patients with advanced esophageal cancer who had conversion surgery lived significantly longer than those who received definitive therapy al…
Jun 6, 2026
Systematic review shows robot-assisted minimally invasive esophagectomy reduces blood loss and hospital stay compared to conventional minimally invasive approaches for resectable esophageal cancer cases involving adult patients
Oncology Meta-analysis
Systematic review shows robot-assisted minimally invasive esophagectomy reduces blood loss and hospital stay compared to conventional minimally invasive approaches for resectable esophageal cancer cases involving adult patients Robotic surgery offers shorter hospital stays for esophageal cancer patients
A systematic review of 13,321 patients indicates robot-assisted minimally invasive esophagectomy offers perioperative benefits like reduced …
A large review found robotic surgery reduces blood loss and hospital time for esophageal cancer patients compared to standard minimally inva…
May 25, 2026
Age and comorbidity do not raise severe complication risk after minimally invasive esophagectomy
Oncology RCT
Age and comorbidity do not raise severe complication risk after minimally invasive esophagectomy Older esophageal cancer patients face no higher risk of severe complications with minimally invasive surgery
A secondary analysis of an RCT found that older age and higher comorbidity were not linked to more severe complications after minimally inva…
Analysis of 245 patients shows age and health conditions do not increase severe complication rates after minimally invasive esophagectomy.
May 16, 2026

Questions about Esophageal Cancer

Do older age or other health issues increase complications after surgery for Esophageal Cancer?

While older age and other health issues are often associated with higher risks in open surgeries, research suggests they may not increase the risk of severe complications for patients undergoing minimally invasive esophagectomy.

Full answer →
Does robot-assisted esophagectomy reduce blood loss and hospital stays for Esophageal Cancer?

Yes, robot-assisted esophagectomy reduces blood loss and hospital stays compared to conventional minimally invasive approaches for esophageal cancer, based on systematic reviews.

Full answer →
Does conversion surgery improve survival rates for patients with cT4 Esophageal Cancer?

Yes, conversion surgery after induction therapy significantly improves survival for cT4 esophageal cancer, with 5-year survival of 26.5% vs 11.6% for definitive therapy alone.

Full answer →
Does EGCG have therapeutic effects on digestive system diseases like Esophageal Cancer?

EGCG shows promise against esophageal cancer in lab and animal studies, and a human trial found it reduced radiation-induced esophagitis, but more clinical research is needed.

Full answer →

All Esophageal Cancer Articles